Seed · Raised $25M · Oct 7, 2026announcement ↗
Rivercell
Backed by
BiotechParis, Francerivercell.ai ↗
🔒 Insider
The founder’s email for Rivercell, with a short intro note already written for you.
What they do
Rivercell is building a cell-response data platform and AI models that predict how human cells change in disease and respond to treatments. Its lab-in-the-loop system combines perturbation experiments, live-cell imaging, gene-expression data, and longitudinal measurements for drug-discovery research. The company is based in Paris and works with biotechnology and pharmaceutical teams.
Hiring outlook
A $25 million seed round suggests hiring across founding and early platform teams, including AI and machine-learning engineers, biotechnology and cell-biology scientists, and specialists in fluidics, automation, and imaging. It may also add early partnerships or business-development roles as it develops collaborations with drug-discovery organizations.
Open roles
Pre-flood window open
Nothing posted yet since the raise, which is exactly when a direct, well-aimed email to a founder beats every job portal. When the postings go up, so does the competition.
Get founders like this to reach you →